<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16533">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01779609</url>
  </required_header>
  <id_info>
    <org_study_id>ET-EX-TRAINING</org_study_id>
    <nct_id>NCT01779609</nct_id>
  </id_info>
  <brief_title>ET-blockade and Exercise-induced Vascular Adaptations in T2DM</brief_title>
  <official_title>Effect of a Dual ET(Endothelin)-Blocker on Exercise Induced Vascular Adaptations in Type 2 Diabetes Mellitus (T2DM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Actelion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to establish the effect of ET blockade on vascular adaptations
      during an 8-week exercise program in subjects with T2DM. We hypothesize that combining ET -
      blockade with exercise training leads to an acute increase of exercise induced blood flow
      when compared with exercise alone. We expect that this will lead to an optimization of
      vascular training effect in T2DM.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Flow mediated dilation</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Conduit Artery Dilator Capacity</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intima-Media Thickness</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal Oxygen Uptake</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Bosentan + Exercise</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2x/day 62.5 mg Bosentan for 4 weeks alongside 3x/week supervised exercise 2x/day 125 mg Bosentan for 4 weeks alongside 3x/week supervised exercise</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Exercise</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2x/day 62.5 mg Placebo for 4 weeks alongside 3x/week supervised exercise 2x/day 125 mg Placebo for 4 weeks alongside 3x/week supervised exercise</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exercise</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>3x/week supervised exercise for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bosentan</intervention_name>
    <arm_group_label>Bosentan + Exercise</arm_group_label>
    <other_name>Bosentan</other_name>
    <other_name>Tracleer</other_name>
    <other_name>actelion pharmaceuticals</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo + Exercise</arm_group_label>
    <other_name>Placebo</other_name>
    <other_name>actelion pharmaceuticals</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Exercise</intervention_name>
    <description>Supervised exercise training program of 8 weeks, for 3x/week</description>
    <arm_group_label>Bosentan + Exercise</arm_group_label>
    <arm_group_label>Placebo + Exercise</arm_group_label>
    <arm_group_label>Exercise</arm_group_label>
    <other_name>Supervised Exercise Training Program</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 Diabetes Mellitus (&gt;2 years since diagnosis) OR controls

        Exclusion Criteria:

          -  &lt;40 years of age

          -  &gt;65 years of age

          -  smoking

          -  cardiovascular disease

          -  diabetes related manifest vascular complications

          -  Type 1 Diabetes Mellitus

          -  use of Glibenclamide

          -  use of HIV drugs

          -  use of calcineurin inhibitors

          -  use of drugs that interfere with CYP3A4 and CYP2C19
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Radboud University Nijmegen Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6525 EX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <lastchanged_date>January 28, 2013</lastchanged_date>
  <firstreceived_date>January 28, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bosentan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
